The role of the P-53 gene and the P-53 protein in non-Hodgkin malignant lymphomas

Not Applicable

Completed

• Conditions: on-Hodgkin malignant lymphomas; Cancer

• Registration Number: ISRCTN12539707
• Lead Sponsor: Titu Maiorescu University

Brief Summary

2018 Other publications in https://doi.org/10.1016/j.biopha.2018.06.072 Review (added 03/05/2023) Results article in https://www.ajsccr.org/article-details.php?tit=AJSCCR-v6-1840 (added 03/05/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-01-15
• Study Start: 2022-11-12
• Last Update Posted: 15 May 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patients diagnosed with CLL-B who were hospitalized in the Hematology departments of the Targu Mures Oncology Institute and Cluj-Napoca between November 2016 and September 2019
2. CLL with> 5000 lymphocytes in absolute value, present at the cytological examination of the blood smear, from the peripheral blood or LLC with less than 10% prolymphocytes based on the peripheral blood smears May-Grunwald Giemsa, stained

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
P-53 isoform protein concentration measured using sandwich ELISA colorimetric quantitative method at a single timepoint

Secondary Outcome Measures

Name	Time	Method
There are no secondary outcome measures